Bhawna Singh¹, Deepak Malkani¹, Prakarshi Kaushik¹, Garima Supyal¹, Pankaj Bhatt¹, Seeta Dewali¹, Netra Pal Sharma¹*, Suraj1, Deepak Chandra Melkani¹ and Satpal Singh Bisht²

¹Department of Zoology, D.S.B. Campus, Kumaun University, Nainital-263002, Uttarakhand, India
²S.S.J. University, Almora, Uttarakhand, India

*Corresponding Author:Netra Pal Sharma, Assistant Professor, Department of Zoology, D.S.B. Campus, Kumaun University, Nainital-263002, Uttarakhand, India.

Received: October 08, 2025; Published: October 25, 2025

Abstract

Millions of people worldwide experience hallucinations caused by psychoactive substances. These hallucinations are a serious problem for both health care and society. The main culprits are hallucinogens like psilocybin, phencyclidine (PCP), methamphetamine, and lysergic acid diethylamide (LSD). These substances lead to perceptual changes characterized by sensory experiences that happen without any external triggers. This study focuses on how these drugs interact with serotonin and dopamine systems and how they affect different areas of the brain. The immediate effects of drug-induced hallucinations can vary widely. They can cause slight visual distortions or lead to severe psychotic episodes. These effects can result in lasting psychological issues, including permanent changes in perception and a greater risk of mental health disorders. The impact goes beyond individual health, affecting social and economic aspects as well. Early diagnosis is essential. It relies on thorough clinical evaluations and toxicological tests to tell apart drug-induced hallucinations from primary psychiatric disorders. Treatment usually includes medications like antipsychotics and psychological support, such as cognitive behavioral therapy and counseling, to help manage symptoms and reduce the chance of relapse. Detox programs and rehab centers are also important for recovery. Recent research into new treatment methods and harm reduction strategies shows potential in reducing the negative effects of these substances. This review highlights the need for a combined approach that involves neuroscience, psychiatry, and public health. Such collaboration can enhance our understanding, prevention, and treatment of drug-induced hallucinations, ultimately benefiting patients and society as a whole.

Keywords: Drug-Induced Hallucinations; Psychoactive Substances; Neurobiological Mechanisms; Psychosis; Antipsychotic Treatment; Cognitive Behavioral Therapy

References

1. American Psychiatric Association. “Diagnostic and Statistical Manual of Mental Disorders”. 5^th, text rev., American Psychiatric Publishing (2022).
2. Nichols David E. "Psychedelics”. Pharmacological Reviews2 (2016): 264-355.
3. Zanos Panos and Todd D Gould. "Mechanisms of Ketamine Action as an Antidepressant”. Molecular Psychiatry4 (2018): 801-811.
4. Wang Gene-Jack., et al. "Partial Recovery of Brain Metabolism in Methamphetamine Abusers after Protracted Abstinence”. American Journal of Psychiatry2 (2002): 313-319.
5. Halberstadt Adam L and Mark A Geyer. "Multiple Receptors Contribute to the Behavioral Effects of Indoleamine Hallucinogens”. Neuropharmacology3 (2011): 364-381.
6. Griffiths R R., et al. "Psilocybin Produces Substantial and Sustained Decreases in Depression and Anxiety in Patients with Life-Threatening Cancer: A Randomized Double-Blind Trial”. Journal of Psychopharmacology12 (2016): 1181-1197.
7. Carbonaro T M., et al. "Survey Study of Challenging Experiences after Ingesting Psilocybin Mushrooms: Acute and Enduring Positive and Negative Consequences”. Journal of Psychopharmacology12 (2016): 1268-1278.
8. Carhart-Harris R L., et al. "Psychedelics and Connectedness”. Psychopharmacology1 (2021): 31-58.
9. Preller Katrin H and Franz X Vollenweider. "Phenomenology, Structure and Dynamic of Psychedelic States”. Handbook of Behavioral Neuroscience, edited by S. R. Pandi-Perumal and D. L. Monti 30, Elsevier (2016): 221-241.
10. Halpern John H., et al. "A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Symptoms in an Online Population”. Drug Testing and Analysis1 (2016): 137-144.
11. Zaremba Laura., et al. "Management of Dextromethorphan-Induced Psychosis: Pharmacological Interventions and Clinical Outcomes”. Biomedicines1 (2023): 123.
12. Aday J S., et al. "Long-Term Effects of Psychedelic Drugs: A Systematic Review”. Neuroscience & Biobehavioral Reviews 113 (2020): 179-189.
13. Orsolini Luca., et al. "The ‘Endless Trip’ Among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen Persisting Perception Disorder. A Systematic Review”. Frontiers in Psychiatry 8 (2017): 240.
14. Martinotti Giovanni., et al. "Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features and Therapeutic Perspectives”. Brain Sciences3 (2018): 47.
15. Vis Jessica C and Annemiek E Goudriaan. "Faces of HPPD: Hallucinogen Persisting Perception Disorder and Its Treatment”. Journal of Addiction Medicine2 (2020): e17-e19.
16. Hermle Leopold., et al. "Hallucinogen-Persisting Perception Disorder”. Therapeutic Advances in Psychopharmacology5 (2012): 199-205.
17. Espiard M L., et al. "Hallucinogen Persisting Perception Disorder after Psilocybin Consumption: A Case Study”. European Psychiatry5-6 (2005): 458-460.
18. Vann Jones Sarah A and Aimee O’Kelly. "Psychedelics in the Treatment of Unipolar Mood Disorders: A Systematic Review”. Journal of Affective Disorders 274 (2020): 1028-1039.
19. Vollenweider Franz X and Michael Kometer. "The Neurobiology of Psychedelic Drugs: Implications for the Treatment of Mood Disorders”. Nature Reviews Neuroscience9 (2010): 642-651.
20. Krystal John H., et al. "Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans”. Archives of General Psychiatry3 (1994): 199-214.
21. Javitt Daniel C and Solomon R Zukin. "Recent Advances in the Phencyclidine Model of Schizophrenia”. American Journal of Psychiatry10 (1991): 1301-1308.
22. Liechti Matthias E. "Modern Clinical Research on MDMA (Ecstasy)”. Pharmacology and Therapeutics 176 (2017): 106-116.
23. Baylen C A and H Rosenberg. "A Review of the Acute Subjective Effects of MDMA/Ecstasy”. Addiction7 (2006): 933-947.
24. Carhart-Harris R L., et al. "Neural Correlates of the Psychedelic State as Determined by fMRI Studies with Psilocybin”. Proceedings of the National Academy of Sciences6 (2012): 2138-2143.
25. Lebedev Alexander V., et al. "Finding the Self by Losing the Self: Neural Correlates of Ego Dissolution under Psilocybin”. Human Brain Mapping8 (2015): 3137-3153.
26. Petri Giovanni., et al. "Homological Scaffolds of Brain Functional Networks”. Journal of The Royal Society Interface101 (2014): 20140873.
27. Johnson Matthew W., et al. "Human Hallucinogen Research: Guidelines for Safety”. Journal of Psychopharmacology6 (2008): 603-620.
28. Schultes Richard Evans., et al. "Plants of the Gods: Their Sacred, Healing and Hallucinogenic Powers”. 2^nd, Healing Arts Press (2001).
29. Carod-Artal F J. "Hallucinogenic Drugs in Pre-Columbian Mesoamerican Cultures”. Neurología (English Edition)1 (2015): 42-49.
30. Winkelman Michael J. "Psychedelics as Medicines for Substance Abuse Rehabilitation: Evaluating Treatments with LSD, Peyote, Ibogaine and Ayahuasca”. Current Drug Abuse Reviews3 (2014): 190-198.
31. Griffiths Roland R., et al. "Psilocybin Can Occasion Mystical-Type Experiences Having Substantial and Sustained Personal Meaning and Spiritual Significance”. Psychopharmacology3 (2006): 268-283.
32. Rätsch Christian. “The Encyclopedia of Psychoactive Plants: Ethnopharmacology and Its Applications”. Inner Traditions (2005).
33. Kometer Michael and Franz X Vollenweider. "Serotonergic Hallucinogen-Induced Visual Hallucinations: Mechanisms, Models and Open Questions”. Current Topics in Behavioral Neurosciences 36 (2016): 139-162.
34. Luke David P and Devin B. Terhune. "The Induction of Synaesthesia with Chemical Agents: A Systematic Review”. Frontiers in Psychology 4 (2013): 753.
35. Barrett FS., et al. "The Challenging Experience Questionnaire: Characterization of Challenging Experiences with Psilocybin Mushrooms”. Journal of Psychopharmacology12 (2016): 1279-1295.
36. Rucker James JH., et al. "Psychiatry and the Psychedelic Drugs: Past, Present and Future”. Neuropharmacology 142 (2018): 200-218.
37. Parrott, Andrew C. "Human Psychobiology of MDMA or 'Ecstasy': An Overview of 25 Years of Empirical Research”. Human Psychopharmacology: Clinical and Experimental4 (2013): 289-307.
38. Morgan Celia J A and H Valerie Curran. "Ketamine Use: A Review”. Addiction1 (2012): 27-38.
39. Griffiths Roland R., et al. "Psilocybin-Occasioned Mystical-Type Experience in Combination with Meditation and Other Spiritual Practices Produces Enduring Positive Changes in Psychological Functioning and in Trait Measures of Prosocial Attitudes and Behaviors”. Journal of Psychopharmacology1 (2018): 49-69.
40. Mitchell Jennifer M., et al. "MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study”. Nature Medicine6 (2021): 1025-1033.
41. Abdallah CG., et al. "Ketamine and Rapid-Acting Antidepressants: A Window into a New Neurobiology for Mood Disorder Therapeutics”. Annual Review of Medicine 66 (2015): 509-523.
42. Hartogsohn Ido. "Set and Setting, Psychedelics and the Placebo Response: An Extra-Pharmacological Perspective on Psychopharmacology”. Journal of Psychopharmacology12 (2016): 1259-1267.
43. Kočovská Eva., et al. "Adverse Events in Psychedelic Therapy: A Review of the Literature and Recommendations for Prevention and Management”. Therapeutic Advances in Psychopharmacology 11 (2021): 1-15.
44. Nutt David J., et al. "Psychedelic Psychiatry’s Brave New World”. Cell1 (2020): 24-28.
45. Andersen K A A., et al. "Therapeutic Use of Classic Psychedelics to Treat Mental Health Conditions”. Current Opinion in Psychiatry1 (2021): 43-50.
46. Yaden David B., et al. "The Future of Psychedelic Science”. JAMA Psychiatry5 (2021): 469-470.
47. Doss M K., et al. "Models of Psychedelic Drug Action: A New Comparative Framework”. Neuroscience & Biobehavioral Reviews 138 (2022): 104676.
48. Cameron L P., et al. "A Non-Hallucinogenic Psychedelic Analogue with Therapeutic Potential”. Nature7842 (2021): 474-479.
49. Kuypers Kevin P C., et al. "Microdosing Psychedelics: More Questions than Answers? An Overview and Suggestions for Future Research”. Journal of Psychopharmacology9 (2019): 1039-1057.
50. George J R., et al. "The Psychedelic Renaissance and the Limitations of Colorblind Mental Health Care”. The American Psychologist6 (2020): 743-754.

Citation

Citation: Netra Pal Sharma., et al. “Hallucinations Induced by Psychoactive Drugs: Mechanisms, Consequences, and Therapeutic Interventions".Acta Scientific Neurology 8.11 (2025): 33-42.

Copyright

Copyright: © 2025 Netra Pal Sharma., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.